Company Overview of DFB Pharmaceuticals, Inc.
DFB Pharmaceuticals, Inc., through its subsidiaries, develops, licenses, and acquires pharmaceutical and medical products that prevent or treat disorders associated with skin and soft tissue. It offers tissue management products to prepare, heal, or treat chronic wounds, such as skin protection products, enzymatic debridement products, wound infection products, and accelerated wound products, as well as biologic and cellular therapies to promote the healing of acute, traumatic, and chronic wounds. The company also provides skin asepsis products, including brush-free surgical scrubs, patient preoperative skin preparations products, and healthcare personnel hand washes. In addition, it offers ...
3909 Hulen Street
Fort Worth, TX 76107
Founded in 1997
Key Executives for DFB Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
President of Coria - DFB Branded Pharmaceuticals
Senior Vice President of Research and Development - Branded Pharmaceuticals
Compensation as of Fiscal Year 2014.
DFB Pharmaceuticals, Inc. Key Developments
Attorney General Cuccinelli Announces Settlement with Healthpoint, Ltd. and DFB Pharmaceuticals, Inc. for Illegal Marketing of Xenaderm
Feb 28 13
Attorney General Ken Cuccinelli announced that it has reached a settlement Healthpoint, Ltd. and its general partner, DFB Pharmaceuticals, for the illegal marketing of Xenaderm, a topical treatment for skin ulcers. The attorney general said that the agreement will resolve allegations that Healthpoint submitted false claims to Virginia's Medicaid program for the unapproved drug. The settlement resolves federal and state False Claims Act cases brought against Healthpoint in the U.S. Federal District Court in Massachusetts. The cases were brought by the U.S. Department of Justice and fifteen plaintiff states. As part of a $48 million settlement announced by the Department of Justice on December 6, 2012, Healthpoint and DFB will pay approximately $33 million total to settle Medicaid-based claims nationally. The settlement will return $223,283.17 to the commonwealth's Medicaid program. The federal and state complaints alleged Healthpoint marketed Xenaderm without FDA approval by modeling it on a pre-1962 drug that the FDA had never reviewed. Additionally, Healthpoint marketed the drug in spite of the FDA's determination in the 1970s that Xenaderm's principal ingredient was less-than-effective for its intended use.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries